Japanese journal of clinical oncology最新文献_第7页

Distinct epidemiology and treatment outcomes between skeletal and extraskeletal Ewing sarcoma in Japan: a population-based study. 日本骨骼和骨骼外尤文氏肉瘤的不同流行病学和治疗结果：一项基于人群的研究

IF 2.5 4区医学

Japanese journal of clinical oncology Pub Date : 2026-09-09 DOI: 10.1093/jjco/hyag086

Yu Toda, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Eisuke Kobayashi, Toshiyuki Takemori, Hiroya Kondo, Shudai Muramatsu, Takahiro Higashi, Akira Kawai

{"title":"Distinct epidemiology and treatment outcomes between skeletal and extraskeletal Ewing sarcoma in Japan: a population-based study.","authors":"Yu Toda, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Eisuke Kobayashi, Toshiyuki Takemori, Hiroya Kondo, Shudai Muramatsu, Takahiro Higashi, Akira Kawai","doi":"10.1093/jjco/hyag086","DOIUrl":"10.1093/jjco/hyag086","url":null,"abstract":"Background: Ewing sarcoma arises at both skeletal (SES) and extraskeletal (EES) sites; however, whether the anatomical origin influences outcomes in current practice remains uncertain. This study compared clinical characteristics, treatment, and survival rates of patients with SES and EES in a large nationwide Japanese cohort.Methods: We analyzed patients diagnosed with Ewing's sarcoma between 2016 and 2019 in Japan, classified as having SES or EES, using a population-based cancer registry. Demographics, stage, treatment, hospital characteristics, and overall survival (OAS) were evaluated using chi-square tests, Kaplan-Meier estimates, and log-rank analyses.Results: We identified 505 patients with ES: 211 with SES and 294 with EES. Patients with EES were significantly older than those with SES (P < .001). Chemotherapy (97.7% vs. 74.9%, P < .001) and radiotherapy (36.6% vs. 27.1%, P = .024) were administered more frequently in the SES group. Three-year OAS rate was 62.3%, 73.5% for SES, and 54.7% for EES, with significantly worse survival in EES group (P < .001). Favorable prognostic factors included younger age, localized stage, surgery, chemotherapy, treatment at certified institutions, higher hospital volume, and female sex among patients with EES.Conclusions: In this nationwide cohort, EES presented at older ages, received less chemotherapy, and demonstrated inferior survival compared to SES, despite a similar stage distribution. Patient background, hospital type, and volume influenced the outcomes. These findings underscore the need for equitable multimodal therapy delivery, particularly for patients with EES.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1044-1051"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148101521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Surgical de-escalation in early-stage cervical cancer: current evidence and future perspectives. 早期子宫颈癌手术降压：当前证据和未来展望

IF 2.5 4区医学

Japanese journal of clinical oncology Pub Date : 2026-09-09 DOI: 10.1093/jjco/hyag092

Atsushi Fusegi, Kyohei Nishikawa, Tsubasa Kon, Mayumi Kamata, Hidetaka Nomura, Hiroyuki Kanao

{"title":"Surgical de-escalation in early-stage cervical cancer: current evidence and future perspectives.","authors":"Atsushi Fusegi, Kyohei Nishikawa, Tsubasa Kon, Mayumi Kamata, Hidetaka Nomura, Hiroyuki Kanao","doi":"10.1093/jjco/hyag092","DOIUrl":"10.1093/jjco/hyag092","url":null,"abstract":"The surgical management of early-stage cervical cancer is undergoing a paradigm shift from a uniform radical approach to a risk-adapted de-escalation strategy. Improved oncologic outcomes have increased long-term survival, bringing attention to the importance of addressing treatment-related morbidity and quality of life. Emerging clinical evidence has challenged the necessity of extensive surgery in selected patients. This narrative review summarizes recent evidence supporting surgical de-escalation across three domains: uterine surgery, nodal management, and surgical approach. Studies were identified through a targeted narrative literature search and selected based on study design, oncologic outcomes, and methodological considerations. For uterine surgery, randomized trials demonstrate that omitting or reducing parametrial resection is oncologically safe for rigorously defined low-risk patients, yielding consistent improvements in postoperative functional outcomes. In nodal management, sentinel lymph node-based strategies allow the omission of systematic pelvic lymphadenectomy without compromising oncologic safety, when strict mapping algorithms and high-quality pathological assessment are applied. For surgical approach, however, de-escalation remains more controversial. Current evidence suggests that oncologic safety in minimally invasive surgery may depend on protocol-driven prevention of intraoperative tumor spillage and appropriate patient selection, but this approach remains investigational. Surgical de-escalation should not be viewed as merely reducing procedures. Rather, it represents a structured, evidence-based strategy incorporating risk stratification, standardized surgical techniques, and rigorous quality assurance. When these prerequisites are met, de-escalation optimally balances oncologic safety with quality-of-life preservation, potentially guiding future tailored surgical strategies for early-stage cervical cancer.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1031-1043"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148239160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging perspectives on RNA-based and RNA-targeted therapeutics in oncology. 肿瘤中基于rna和靶向rna治疗的新观点。

IF 2.5 4区医学

Japanese journal of clinical oncology Pub Date : 2026-09-07 DOI: 10.1093/jjco/hyag149

Akihide Yoshimi

引用次数: 0

Splicing modulation as an emerging therapeutic strategy in cancer: molecular mechanisms, clinical development, and future perspectives. 剪接调节作为一种新兴的癌症治疗策略：分子机制、临床发展和未来展望。

IF 2.5 4区医学

Japanese journal of clinical oncology Pub Date : 2026-09-07 DOI: 10.1093/jjco/hyag140

Xinbate Jingele, Qinxinru Sun, Xiaoyang Li, Xinyu Li, Ayana Kon, Xuerui Tao, Akihide Yoshimi

{"title":"Splicing modulation as an emerging therapeutic strategy in cancer: molecular mechanisms, clinical development, and future perspectives.","authors":"Xinbate Jingele, Qinxinru Sun, Xiaoyang Li, Xinyu Li, Ayana Kon, Xuerui Tao, Akihide Yoshimi","doi":"10.1093/jjco/hyag140","DOIUrl":"https://doi.org/10.1093/jjco/hyag140","url":null,"abstract":"Aberrant pre-mRNA splicing is a pervasive feature of cancer and an emerging therapeutic vulnerability. Recurrent mutations in core spliceosomal components, including SF3B1, SRSF2, U2AF1, and ZRSR2, are common in myeloid malignancies, while dysregulated splicing regulators and cis-acting splice-site alterations shape cancer-relevant isoform programs across solid tumors. Together with high transcriptional output, rapid proliferation, and oncogene-driven RNA-processing demand, these alterations can reduce the capacity of cancer cells to tolerate additional splicing perturbation, creating a therapeutic window for pharmacological splicing modulation. Multiple strategies are under investigation, including SF3B complex modulators, splicing kinase inhibitors, RBM39-directed molecular glues, PRMT/arginine-methylation-directed approaches, and selected splice-switching strategies. Early clinical experience indicates that pharmacodynamic modulation of splicing is achievable in patients, yet objective clinical benefit has been inconsistent. This reflects narrow therapeutic windows, incomplete concordance between peripheral-blood pharmacodynamic markers and tumor-tissue splicing perturbation, and the limited predictive value of mutation status alone. Rational combinations with apoptosis-targeted agents, oncogene-directed therapies, DNA-damaging agents, PARP inhibitors, and immunotherapies may offer a more effective route to clinical translation than maximal single-agent splicing inhibition. Continued progress will require more selective splicing-directed modalities, pharmacodynamic biomarkers that measure splicing perturbation in the relevant tumor or blood compartment, longitudinal mapping of genetic and tumor cell-state plasticity-driven resistance, and biomarker-defined combination trials to support expansion from hematologic malignancies into solid tumors.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PDGFRA amplification could be a poor prognostic factor of advanced undifferentiated pleomorphic sarcoma in a comprehensive genomic profiling cohort. 在一个全面的基因组分析队列中，PDGFRA扩增可能是晚期未分化多形性肉瘤的不良预后因素。

IF 2.5 4区医学

Japanese journal of clinical oncology Pub Date : 2026-09-07 DOI: 10.1093/jjco/hyag147

Hiroshi Kobayashi, Masachika Ikegami, Liuzhe Zhang, Koichi Okajima, Toshihiko Ando, Toshihide Hirai, Yusuke Tsuda, Sakae Tanaka

{"title":"PDGFRA amplification could be a poor prognostic factor of advanced undifferentiated pleomorphic sarcoma in a comprehensive genomic profiling cohort.","authors":"Hiroshi Kobayashi, Masachika Ikegami, Liuzhe Zhang, Koichi Okajima, Toshihiko Ando, Toshihide Hirai, Yusuke Tsuda, Sakae Tanaka","doi":"10.1093/jjco/hyag147","DOIUrl":"https://doi.org/10.1093/jjco/hyag147","url":null,"abstract":"Background: Undifferentiated pleomorphic sarcoma (UPS) is the most common pleomorphic sarcoma, and its genomic landscape has been analysed, albeit in small numbers. This study aimed to clarify the relationship between gene variants and the prognosis of patients with advanced UPS.Methods: This retrospective cohort study was conducted to analyse the data of patients with advanced UPS using a registry of the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database up to Oct 2025 in Japan, analysed using comprehensive genomic profiling assay.Results: A total of 233 patients with advanced UPS were identified in the C-CAT database; 151 men (64.8%), median age: 60.2 years. TP53 variant (55%) was the most frequent event and the rate of Platelet-derived growth factor receptor alpha (PDGFRA) and KDR amplification were 9% and 6%, respectively. PDGFRA amplification co-occurred with KDR amplification (P < 0.001). Survival from the initiation of chemotherapy was analysed by adjusting for length bias inherent in the database using the Kaplan-Meier estimator, an established method of adjustment. Patients with PDGFRA amplification (11 patients) had a worse prognosis than those without PDGFRA amplification [hazard ratio 2.9, 95% confidence interval 1.2-6.9 (P = 0.02)]. TP53 alterations (P = 0.24) were not associated with prognosis. In addition, treatment time with pazopanib with PDGFRA amplification [4 patients, 2.3 months (1.2-11.2 months)] was not different with those without PDGFRA amplification [28 patients, 3.8 months (0.9 months-not reached)] (P = 0.52).Conclusions: For patients with advanced UPS, PDGFRA amplification was a poor prognostic factor and is not related to the efficacy of pazopanib treatment.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A reanalysis of the Hitachi cohort study evaluating the effectiveness of low-dose CT screening for lung cancer. 对评估肺癌低剂量CT筛查有效性的日立队列研究的再分析。

IF 2.5 4区医学

Japanese journal of clinical oncology Pub Date : 2026-09-01 DOI: 10.1093/jjco/hyag138

Keisuke Fukui, Takeshi Nawa, Tomio Nakayama, Motoyasu Sagawa

引用次数: 0

Darolutamide-based triplet therapy versus androgen receptor pathway inhibitor-based doublet therapy for metastatic castration-sensitive prostate cancer: a real-world analysis using the TriNetX database. 基于darolutamide的三重疗法与基于雄激素受体途径抑制剂的双重疗法治疗转移性去势敏感前列腺癌：使用TriNetX数据库的现实世界分析

IF 2.5 4区医学

Japanese journal of clinical oncology Pub Date : 2026-08-28 DOI: 10.1093/jjco/hyag145

Yoichiro Tohi, Yuri Kitadani, Takuma Kato, Shunsuke Nakamura, Naoya Kani, Iori Matsuda, Kana Kohashiguchi, Yohei Abe, Hirohito Naito, Homare Okazoe, Rikiya Taoka, Fumiaki Mikami, Mikio Sugimoto

{"title":"Darolutamide-based triplet therapy versus androgen receptor pathway inhibitor-based doublet therapy for metastatic castration-sensitive prostate cancer: a real-world analysis using the TriNetX database.","authors":"Yoichiro Tohi, Yuri Kitadani, Takuma Kato, Shunsuke Nakamura, Naoya Kani, Iori Matsuda, Kana Kohashiguchi, Yohei Abe, Hirohito Naito, Homare Okazoe, Rikiya Taoka, Fumiaki Mikami, Mikio Sugimoto","doi":"10.1093/jjco/hyag145","DOIUrl":"https://doi.org/10.1093/jjco/hyag145","url":null,"abstract":"Background: Currently, there are no large cohort studies comparing the clinical outcomes of triplet therapy with those of androgen receptor pathway inhibitor (ARPI)-based doublet therapy for patients with metastatic castration-sensitive prostate cancer (mCSPC) representing real-world practice. Therefore, the present study aimed to compare whether triplet or doublet therapy is more effective in patients with mCSPC.Methods: This large-scale retrospective cohort study used TriNetX electronic medical record data from August 2018 to July 2026, enrolling patients with mCSPC categorized as receiving triplet [darolutamide + docetaxel + androgen deprivation therapy (ADT)] or doublet therapy (enzalutamide or apalutamide + ADT). The primary outcome was overall survival (OS), while the secondary outcome was the proportion of patients achieving a PSA level ≤ 0.2 ng/ml. Propensity score matching (PSM) (1:1) was conducted to adjust for confounding variables between groups.Results: Overall, 1841 patients met the eligibility criteria. Following PSM (n = 329), triplet therapy was associated with a statistically significant improvement in OS compared with doublet therapy (hazard ratio: 0.601; 95% confidence interval: 0.420-0.862; log-rank P = .005). The proportions of patients achieving PSA ≤0.2 ng/ml were 26.4% vs. 17.0% at 3 months (P = .003), 37.4% vs. 27.7% at 6 months (P = .008), 43.8% vs. 35.9% at 12 months (P = .038), and 50.5% vs. 40.1% at any time (P = .008) in the triplet and doublet groups, respectively.Conclusions: In this real-world analysis using the TriNetX database, triplet therapy including darolutamide significantly improved OS and PSA decline compared with ARPI-based doublet therapy.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enfortumab vedotin plus pembrolizumab for recurrent metastatic urothelial carcinoma following adjuvant nivolumab. 辅助纳武单抗治疗复发性转移性尿路上皮癌。

IF 2.5 4区医学

Japanese journal of clinical oncology Pub Date : 2026-08-28 DOI: 10.1093/jjco/hyag143

Lan Inoki, Saizo Fujimoto, Mamoru Hashimoto, Yutaka Yamamoto, Teruo Inamoto, Keita Tamura, Takuhisa Nukaya, Kiyoshi Takahara, Wataru Fukuokaya, Takafumi Yanagisawa, Yuki Yoshikawa, Ryoichi Maenosono, Hirofumi Morinaka, Seitetsu Sugiyama, Kazutoshi Fujita

{"title":"Enfortumab vedotin plus pembrolizumab for recurrent metastatic urothelial carcinoma following adjuvant nivolumab.","authors":"Lan Inoki, Saizo Fujimoto, Mamoru Hashimoto, Yutaka Yamamoto, Teruo Inamoto, Keita Tamura, Takuhisa Nukaya, Kiyoshi Takahara, Wataru Fukuokaya, Takafumi Yanagisawa, Yuki Yoshikawa, Ryoichi Maenosono, Hirofumi Morinaka, Seitetsu Sugiyama, Kazutoshi Fujita","doi":"10.1093/jjco/hyag143","DOIUrl":"https://doi.org/10.1093/jjco/hyag143","url":null,"abstract":"Adjuvant nivolumab is an established postoperative treatment for high-risk urothelial carcinoma, but evidence for subsequent enfortumab vedotin plus pembrolizumab (EVP) after recurrence is limited. We retrospectively evaluated 17 patients with locally advanced or metastatic urothelial carcinoma who received EVP after recurrence following adjuvant nivolumab in a Japanese multi-institutional cohort. Among 16 response-evaluable patients, the objective response rate was 68.8% (11/16; exact 95% confidence interval [CI]: 41.3%-89.0%), including four complete responses and seven partial responses. Responses were observed across nivolumab-free interval groups. Median progression-free survival was 5.2 months (95% CI, 2.5-not estimable), and the median overall survival was not reached (95% CI, 8.4-not estimable). Grade 3 or higher adverse events occurred in three patients (17.6%), and one treatment-related death was recorded. These findings suggest clinically meaningful antitumor activity of EVP after recurrence following adjuvant nivolumab, warranting confirmation in larger comparative studies.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Programmed death-ligand 1 expression in gastric cancer by the combined positive score using the PD-L1 IHC 28-8 pharmDx test: a single institution's experience. 使用PD-L1 IHC 28-8 pharmDx测试联合阳性评分检测胃癌中程序性死亡配体1的表达：单个机构的经验。

IF 2.5 4区医学

Japanese journal of clinical oncology Pub Date : 2026-08-28 DOI: 10.1093/jjco/hyag144

Tomomi Hamaguchi, Kyoko Furusawa, Mamoru Watanabe, Kei Hayashi, Mitsuhiro Furuta, Yasuhiro Inokuchi, Satoshi Kobayashi, Makoto Ueno, Yuta Nakayama, Mie Tanabe, Junya Morita, Kyohei Kanematsu, Shinsuke Nagasawa, Takanobu Yamada, Takashi Ogata, Takashi Oshima, Tomoyuki Yokose, Nozomu Machida, Junji Furuse, Shin Maeda

{"title":"Programmed death-ligand 1 expression in gastric cancer by the combined positive score using the PD-L1 IHC 28-8 pharmDx test: a single institution's experience.","authors":"Tomomi Hamaguchi, Kyoko Furusawa, Mamoru Watanabe, Kei Hayashi, Mitsuhiro Furuta, Yasuhiro Inokuchi, Satoshi Kobayashi, Makoto Ueno, Yuta Nakayama, Mie Tanabe, Junya Morita, Kyohei Kanematsu, Shinsuke Nagasawa, Takanobu Yamada, Takashi Ogata, Takashi Oshima, Tomoyuki Yokose, Nozomu Machida, Junji Furuse, Shin Maeda","doi":"10.1093/jjco/hyag144","DOIUrl":"https://doi.org/10.1093/jjco/hyag144","url":null,"abstract":"Background: Programmed death-ligand 1 (PD-L1) Combined Positive Score (CPS) is a biomarker of nivolumab efficacy in advanced gastric cancer (AGC). Reported CPS ≥ 5 in AGC has been inconsistent across studies. We aimed to examine the distribution of CPS in real-world clinical practice using the Dako PD-L1 IHC 28-8 pharmDx (Dako 28-8) assay and to evaluate its clinical utility.Methods: We retrospectively assessed CPS using Dako 28-8 in 138 patients with AGC treated at our institution between January 2022 and December 2022.Results: The numbers of patients with CPS ≥ 5, 1 ≤ CPS < 5, and CPS < 1 were 65 (47.1%), 50 (36.2%), and 23 (16.7%), respectively. Among the patients evaluated for microsatellite instability (MSI) or tumor mutation burden (TMB), MSI-high was identified in 3/32 (9.4%), 2/31 (6.5%), and 1/20 (5.0%), while TMB-high was identified in 5/14 (35.7%), 4/20 (20.0%), and 2/11 (18.2%) in the CPS ≥ 5, 1 ≤ CPS < 5, and CPS < 1 groups, respectively. Nivolumab combination therapy was administered as first-line treatment in 14, 10, and 11 patients in the CPS ≥ 5, 1 ≤ CPS < 5, and CPS < 1 groups, respectively. Median Progression-free survival was 5.6 months in CPS ≥ 5, 5.9 months in 1 ≤ CPS < 5, and 6.5 months in CPS < 1.Conclusion: The frequency of CPS ≥5 in patients with AGC was approximately half of the total population. Because TMB-high tumors were identified in some patients with CPS < 5, further studies are needed to clarify the potential role of TMB in predicting ICI responsiveness in this population.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical features and treatment outcomes of fibrous dysplasia: a report from the Bone and Soft Tissue Tumor Registry in Japan. 纤维性发育不良的临床特征和治疗结果：来自日本骨和软组织肿瘤登记处的报告。

IF 2.5 4区医学

Japanese journal of clinical oncology Pub Date : 2026-08-28 DOI: 10.1093/jjco/hyag142

Masayuki Morishita, Daisuke Kobayashi, Akira Ogose, Akira Kido, Akihiko Takeuchi, Kazu Matsumoto, Kota Watanabe, Yoji Furukawa, Michio Ozeki, Akira Kawai, Yoshihiro Nishida

{"title":"Clinical features and treatment outcomes of fibrous dysplasia: a report from the Bone and Soft Tissue Tumor Registry in Japan.","authors":"Masayuki Morishita, Daisuke Kobayashi, Akira Ogose, Akira Kido, Akihiko Takeuchi, Kazu Matsumoto, Kota Watanabe, Yoji Furukawa, Michio Ozeki, Akira Kawai, Yoshihiro Nishida","doi":"10.1093/jjco/hyag142","DOIUrl":"https://doi.org/10.1093/jjco/hyag142","url":null,"abstract":"Background: Fibrous dysplasia (FD) is a benign bone disorder classified into monostotic (MFD) and polyostotic (PFD) forms. There is limited evidence available regarding the clinical management of FD, and no large-scale epidemiological or treatment reports have been published from Japan. Therefore, this study aimed to clarify FD epidemiology and management using data from the nationwide Bone and Soft Tissue Tumor (BSTT) Registry.Methods: This study retrospectively analyzed patients with MFD and PFD registered in the BSTT Registry between 2008 and 2019. The data included patient demographics, tumor location, surgical treatment, and recurrence. Local control survival (LCS) was estimated using the Kaplan-Meier method and compared using a log-rank test.Results: In total, 3181 FD cases were registered from 127 institutions (MFD, 2889; 90.8%; PFD, 292; 9.2%). The femur was the most frequently affected site in both groups. Intralesional curettage was the most frequently performed surgical procedure, accounted for in 66.9% of MFD cases and 60.8% of PFD cases. Local recurrence occurred in 2.6% and 4.2% of patients with MFD and PFD, respectively. The 1-year overall LCS rate was 97.4%, with no significant differences between groups.Conclusion: This study provides the largest dataset of FD in Japan, contributing to a better understanding of its epidemiology and surgical management. However, limitations, such as the underrepresentation of pediatric cases, incomplete data on non-surgical treatments, and deformity correction procedures, highlight the need for more comprehensive data to inform future treatment strategies.","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0